Akero Therapeutics (AKRO) News Today → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free AKRO Stock Alerts $21.02 -1.00 (-4.54%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAkero Therapeutics to Present at the BofA Securities 2024 Health Care Conferenceglobenewswire.com - May 8 at 7:00 AMAKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!prnewswire.com - May 8 at 4:00 AMAkero Therapeutics (AKRO) Slides After Failed Trial, Hit With Class Action Lawsuit - Hagens Bermanstockhouse.com - May 7 at 10:50 PMROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKROprnewswire.com - May 7 at 5:37 PMClass Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc.prnewswire.com - May 7 at 3:05 PMGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investorsbusinesswire.com - May 7 at 2:02 PMThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investorsstockhouse.com - May 6 at 7:17 PMINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firmmarkets.businessinsider.com - May 6 at 7:17 PMAkero Therapeutics (NASDAQ:AKRO) Trading 5.5% Higher marketbeat.com - May 6 at 6:31 PMINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investorsbusinesswire.com - May 6 at 12:00 PMONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeuticsmarkets.businessinsider.com - May 5 at 4:35 PMAKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors Can Join the Class Action Lawsuit!stockhouse.com - May 5 at 9:21 AMJonathan Young Sells 5,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stockamericanbankingnews.com - May 4 at 5:32 AMAKERO THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROprnewswire.com - May 3 at 10:45 PMINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firmmarkets.businessinsider.com - May 3 at 6:19 PMGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investorsbusinesswire.com - May 3 at 10:00 AMAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $100,750.00 in Stockinsidertrades.com - May 3 at 7:30 AMGrabar Law Office Investigates Claims on Behalf of Shareholders of Akero Therapeutics, Inc. (AKRO)markets.businessinsider.com - May 3 at 3:15 AMSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firmmarkets.businessinsider.com - May 2 at 9:58 PMAkero Therapeutics, Inc. (AKRO) Investor Notice: Robbins LLP Reminds Stockholders of the Akero Therapeutics, Inc. Class Actionbusinesswire.com - May 2 at 9:29 PMINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investorsbusinesswire.com - May 2 at 5:31 PMAKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuitbusinesswire.com - May 2 at 3:59 PMThe Law Offices of Frank R. Cruz Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investorsbusinesswire.com - May 2 at 2:47 PMDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeuticsmarkets.businessinsider.com - May 2 at 8:29 AMClass Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc.prnewswire.com - May 2 at 7:30 AMAKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!prnewswire.com - May 1 at 9:41 PMSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firmprnewswire.com - May 1 at 11:15 AMNASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.prnewswire.com - May 1 at 9:15 AMNASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.businesswire.com - April 30 at 10:35 PMAKRO INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action -AKROprnewswire.com - April 30 at 9:15 PMSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firmmarkets.businessinsider.com - April 30 at 7:18 PMAkero Therapeutics Appoints Scott Gangloff as Chief Technology Officerglobenewswire.com - April 30 at 8:00 AM71,542 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Purchased by abrdn plcmarketbeat.com - April 30 at 4:46 AMSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKROprnewswire.com - April 29 at 5:28 PMROSEN, LEADING INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRObusinesswire.com - April 29 at 11:47 AMAKRO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuitbusinesswire.com - April 29 at 7:45 AMAKERO THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRObusinesswire.com - April 28 at 5:04 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKROprnewswire.com - April 28 at 9:45 AMBenjamin Graham Detailed Fundamental Analysis - AKROnasdaq.com - April 24 at 1:58 PMAkero Therapeutics (NASDAQ:AKRO) Now Covered by Bank of Americamarketbeat.com - April 22 at 8:35 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKROprnewswire.com - April 20 at 12:15 PMShort Interest in Akero Therapeutics, Inc. (NASDAQ:AKRO) Drops By 17.2%marketbeat.com - April 13 at 10:59 AMAkero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoingsstockhouse.com - April 7 at 8:24 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKROprnewswire.com - April 4 at 7:25 PMAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 5,000 Sharesinsidertrades.com - April 4 at 6:41 AMInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 5,000 Shares of Stockmarketbeat.com - April 3 at 9:42 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Akero Therapeutics, Inc. - AKROstockhouse.com - April 3 at 6:39 PMAkero Therapeutics' EFX Data Warrants Cautionseekingalpha.com - April 3 at 3:37 AMAdemi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc.prnewswire.com - April 2 at 6:05 PMVanguard Group Inc. Purchases 326,308 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)marketbeat.com - April 2 at 4:10 AM Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Gold Set to EXPLODE! (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025. Click here now to download the free Precious Metals Buying Guide! AKRO Media Mentions By Week AKRO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼0.120.36▲Average Medical News Sentiment AKRO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼244▲AKRO Articles Average Week Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Protagonist Therapeutics News Morphic News Dynavax Technologies News Xencor News Day One Biopharmaceuticals News Taro Pharmaceutical Industries News Kiniksa Pharmaceuticals News Kura Oncology News Arcus Biosciences News ANI Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDems have chosen Biden replacement?Paradigm PressThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetryTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
